AKT2 Inhibitors
1 drugsAbout AKT2
AKT2, or Protein Kinase B beta (PKBβ), is a serine/threonine kinase involved in cell survival, proliferation, and metabolism via the PI3K/AKT/mTOR pathway. It regulates cell growth and survival, making it a compelling target for drug development.
Currently, there is no genetic evidence directly linking AKT2 to specific diseases. However, its role in the PI3K/AKT/mTOR pathway, a key regulator of cell growth, makes it a potential therapeutic target, particularly in oncology.
AKT2 is targeted by one FDA-approved drug, TRUQAP (AstraZeneca), a small molecule for oncology indications. AstraZeneca is the only company with an approved drug for this target.
Top AKT2 Drugs
AstraZeneca is the only company with an approved drug targeting AKT2.
The lack of competitors indicates high entry barriers or untapped potential in the AKT2 space.
AKT2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets AKT2, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
AKT2 Clinical Trials 44 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on AKT2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 8 | 0 | 13 | 100% |
| Phase 2 | 12 | 1 | 2 | 9 | 33% |
| Phase 3 | 11 | 0 | 0 | 11 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved AKT2 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting AKT2. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
AKT2 Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for AKT2 was TRUQAP in 2023.
Recent approval suggests renewed interest in AKT2, but market saturation could quickly occur.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on AKT2. A trial counts if an approved drug acting on AKT2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.